Sanofi price target raised to $60 from $55 at Argus

Argus analyst Jasper Hellweg raised the firm’s price target on Sanofi to $60 from $55 and keeps a Buy rating on the shares. Argus likes Sanofi’s diverse range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products, and Sanofi has a strong new drug pipeline of 84 molecular entities and vaccine candidates, of which 28 are in Phase 3 trials or have been submitted for regulatory approval, the analyst tells investors in a research note.